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Introduction {#sec001}
============

Endobronchial tuberculosis (EBTB) is defined as *Mycobacterium tuberculosis* (MTB) infection of the tracheobronchial tree with or without lung parenchymal involvement \[[@pone.0234558.ref001]\]. The reported incidence of EBTB varies from 4.1% to 54.3% \[[@pone.0234558.ref002], [@pone.0234558.ref003]\]. The pathogenesis of EBTB is not fully understood, but the beginning of infection includes direct implantation of MTB into the bronchus from the adjacent lung parenchyma or mediastinal lymph nodes, hematogenous or lymphatic spread, or implantation of organisms from infected sputum \[[@pone.0234558.ref004]\]. On the other hand, pathologic endobronchial mucosal changes caused by MTB range from simple erythema, submucosal congestion, caseous necrosis due to loss of mucosal integrity, ulcer formation, and fibrostenosis \[[@pone.0234558.ref004]\]. Although these changes are closely related to the deterioration of symptoms and prognosis, there are still limitations to a precise understanding of the variable course at EBTB \[[@pone.0234558.ref005], [@pone.0234558.ref006]\].

Chronic inflammatory lung disease harbors distinct respiratory bacterial communities and these microorganisms may be associated with the pathogenesis and prognosis of the disease \[[@pone.0234558.ref007]--[@pone.0234558.ref010]\]. Patients with structural lung disease such as chronic obstructive pulmonary disease (COPD), bronchiectasis, or interstitial lung disease are chronically infected with potentially pathogenic microorganisms, resulting in persistent respiratory symptoms and recurrent exacerbation of disease \[[@pone.0234558.ref011]--[@pone.0234558.ref013]\]. Similarly, the endobronchial mucosal changes in EBTB cause local airway inflammation, further airway damage or remodeling, and MTB can form biofilms, which can be altered respiratory microorganisms \[[@pone.0234558.ref014]\]. However, little is known about lung microorganisms in patients with EBTB.

In this study, we analyzed data from EBTB patients and their bronchial washing and investigated the prevalence and composition of respiratory microorganisms.

Materials and methods {#sec002}
=====================

Study population {#sec003}
----------------

We retrospectively reviewed data for EBTB patients diagnosed at Wonju Severance Christian Hospital, a tertiary referral hospital in South Korea, between January 2013 and January 2019. Patients were included as follows: (1) typical bronchoscopic finding of EBTB and (2) histopathologic and microbiological evidence of MTB in endobronchial biopsy specimens and bronchial washing \[[@pone.0234558.ref004]\]. The histopathologic findings include chronic granulomatous inflammation, chronic inflammation, erosion, ulcer, or caseous necrosis \[[@pone.0234558.ref004]\]. We identified 2,425 patients with active pulmonary tuberculosis between January 2013 and January 2019. We excluded 895 patients because bronchoscopy was not performed and 1,314 patients had inconsistent bronchoscopic findings or histologic features of EBTB. The final number of study participants was 216.

Bronchoscopic procedures {#sec004}
------------------------

All bronchoscopy procedures were performed by attending physicians at the time of EBTB diagnosis. All procedures were performed via the trans-nasal or oral route under local anesthesia. Oxygen was administered via nasal cannula and oxygen saturation was maintained at \> 90% as measured by continuous pulse oximetry monitoring. Midazolam at 0.07 mg/kg was delivered intravenously when needed to achieve adequate sedation prior to the procedure. Bronchial washing and bronchoscopic biopsy were performed on suspected endobronchial lesions. Bronchial washing fluid was collected using the suction channel into a trap \[[@pone.0234558.ref015], [@pone.0234558.ref016]\]. Bronchoalveolar lavage was not performed because we did not undertake a wedge position within the selected bronchopulmonary segment due to endobronchial mucosal changes caused by MTB \[[@pone.0234558.ref017]\].

Bacterial detection {#sec005}
-------------------

All bronchial washing specimens were included in the study. All specimens were examined for bacterial pathogens using the Gram stain method and bacterial identification was performed using automatic MicroScan WalkAway 96 Plus (Beckman Coulter, Brea, CA, USA) or VITEK 2 (bioMérieux Inc., Hazelwood, MO, USA) diagnostic systems. Additionally, all specimens were stained using the Ziehl-Neelsen method and cultured using both solid (3% Ogawa medium; Korean Institute of Tuberculosis, Korea) and liquid (BACTEC 960 Mycobacterial Growth Indicator Tube; Becton Dickinson, Sparks, MD, USA) media.

Positive acid-fast bacilli (AFB) stains were described as 1+ to 4+ (1+, 1--9 AFB/100 fields; 2+, 1--9 AFB/10 fields; 3+, 1--9 AFB/field; and 4+, \> 9 AFB/field) \[[@pone.0234558.ref018]\].

Data collection {#sec006}
---------------

Demographic and clinical data were collected from medical chart review including age, sex, body mass index (BMI), smoking history, comorbidities, respiratory symptoms, chest computed tomographic (CT) findings, white blood cell (WBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and bronchial washing results (i.e., AFB smear, mycobacterial culture, and Gram stain culture). Bronchoscopic findings were classified into seven subtypes: actively caseating, edematous-hyperemic, fibrostenotic, tumorous, granular, ulcerative, and nonspecific bronchitic \[[@pone.0234558.ref004]\]. Cases with two or more endobronchial involvement subtypes were classified by the dominant form. The involved site of EBTB was classified as the trachea, main bronchus, right bronchus intermedius (RBI), or lobar bronchus. EBTB with two or more involved bronchial levels was defined as multiple-level involvement, which was described separately for each lesion.

Ethics approval {#sec007}
---------------

This study was approved by the Institutional Review Board for Human Research of Yonsei University Wonju Severance Christian Hospital (CR-319113). The requirement for informed consent was waived because of the retrospective nature of the study. Further, patient data were deidentified before data access and analysis.

Statistical analysis {#sec008}
--------------------

Data are presented as the median with interquartile range (IQR) or the number of patients with the percentages of the total. Continuous variables were compared using the Mann-Whitney U test. Categorical variables were compared using the Pearson's chi-square test or the Fisher's exact test. A *p*-value less than 0.05 was considered statistically significant. Statistical analysis was conducted using SPSS for Windows, version 23.0 (IBM Co., Chicago, IL, USA).

Results {#sec009}
=======

Baseline characteristics {#sec010}
------------------------

A total of 216 patients were included and the baseline characteristics are shown in [Table 1](#pone.0234558.t001){ref-type="table"}. The median age of patients was 73 years, 142 (65.7%) were female, and the median BMI was 21.4 kg/m^2^. The number of patients that never smoked was 155 (71.8%) and those with a history of previous MTB treatment totaled 32 (14.8%) patients. The common comorbidities were diabetes (n = 47, 21.8%) and chronic kidney disease (n = 9, 4.2%). The most common predominant symptoms included cough or sputum (n = 132, 61.1%) followed by hemoptysis (n = 12, 5.6%); however, 61 (28.2%) patients were asymptomatic at the time of diagnosis. In chest CT findings, pulmonary consolidation and cavities were observed in 128 (59.3%) and 31 (14.4%) patients, respectively. On the contrary, 32 (14.8%) patients had no active lung parenchymal lesions on images. The median WBC, ESR, and CRP were 6,820 /μL, 50 mm/h, and 1.76 mg/dL, respectively. In bronchial washing specimens, AFB smears were positive in 149 (69.0%) patients.

10.1371/journal.pone.0234558.t001

###### Baseline characteristics.

![](pone.0234558.t001){#pone.0234558.t001g}

                                                                             Overall (*n* = 216)
  -------------------------------------------------------------------------- ----------------------
  Age, years                                                                 73 (55--79)
  Gender, female                                                             142 (65.7%)
  Body mass index, kg/m^2^                                                   21.4 (19.7--23.6)
  Smoking history                                                            
   Never smoker                                                              155 (71.8%)
  History of MTB treatment                                                   32 (14.8%)
  Comorbidities                                                              
   Diabetes                                                                  47 (21.8%)
   Chronic kidney disease                                                    9 (4.2%)
  Respiratory symptoms[\*](#t001fn001){ref-type="table-fn"}                  
   Cough or sputum                                                           132 (61.1%)
   Hemoptysis                                                                12 (5.6%)
   Asymptomatic                                                              61 (28.2%)
  Chest computed tomographic findings[\*](#t001fn001){ref-type="table-fn"}   
   Consolidation                                                             128 (59.3%)
   Cavity                                                                    31 (14.4%)
   No active lung parenchymal lesion                                         32 (14.8%)
  Laboratory findings                                                        
   White blood cell, /μL                                                     6,820 (5,565--8,625)
   Erythrocyte sedimentation rate, mm/h                                      50 (29--67)
   C-reactive protein, mg/dL                                                 1.76 (0.50--5.29)
  AFB stain[^†^](#t001fn002){ref-type="table-fn"}                            
   0                                                                         67 (31.0%)
   1+                                                                        68 (31.5%)
   2+                                                                        39 (18.1%)
   3+                                                                        29 (13.4%)
   4+                                                                        13 (6.0%)

\* Cases are duplicated.

^†^ Positive acid-fast bacilli (AFB) stains were described as 1+ to 4+ (1+, 1--9 AFB/100 fields; 2+, 1--9 AFB/10 fields; 3+, 1--9 AFB/field; and 4+, \> 9 AFB/field).

Values are presented as median (interquartile range) or count (percentage).

MTB, *Mycobacterium tuberculosis*; AFB, acid-fast bacilli

Bronchoscopic findings {#sec011}
----------------------

The bronchoscopic features of EBTB are shown in [Table 2](#pone.0234558.t002){ref-type="table"}. Actively caseating, edematous-hyperemic, fibrostenotic, and nonspecific bronchitic type were observed in 114 (52.8%), 32 (14.8%), 33 (15.3%), and 18 (8.3%) patients, respectively. The most commonly involved site was the lobar bronchi (n = 194, 89.8%) followed by the main bronchi or the right bronchus intermedius (n = 42, 19.4%), and trachea (n = 11, 5.1%), respectively. Twenty-nine (13.4%) patients had multiple levels of bronchial involvement.

10.1371/journal.pone.0234558.t002

###### Bronchoscopic features.

![](pone.0234558.t002){#pone.0234558.t002g}

                                                        Overall (*n* = 216)
  ----------------------------------------------------- ---------------------
  Bronchoscopic finding                                 
   Actively caseating                                   114 (52.8%)
   Edematous-hyperemic                                  32 (14.8%)
   Fibrostenotic                                        33 (15.3%)
   Other types[\*](#t002fn001){ref-type="table-fn"}     37 (17.1%)
  Site involved[^‡^](#t002fn002){ref-type="table-fn"}   
   Trachea                                              11 (5.1%)
   Main bronchi or RBI                                  42 (19.4%)
   Lobar bronchi                                        194 (89.8%)
  Levels involved                                       
   Single                                               187 (86.6%)
   Multiple                                             29 (13.4%)

\* Including tumorous (n = 5), granular (n = 5), ulcerative (n = 9), and nonspecific bronchitic type (n = 18)

^‡^ EBTB with multiple-level involvement was counted for each involvement.

Values are presented as count (percentage).

RBI, right bronchus intermedius; EBTB, endobronchial tuberculosis

Microbiological characteristics {#sec012}
-------------------------------

Microbiological characteristics of the bronchial washing samples are shown in [Table 3](#pone.0234558.t003){ref-type="table"}. Apart from MTB, bacteria were detected in 42 (19.4%) patients and 6 (2.8%) of them had multiple microbial species. A total of 19 bacterial species were isolated. Apart from MTB, the most common microorganisms identified were *Staphylococcus aureus* (n = 14, 33.3%) including 8 cases of methicillin-sensitive *S*. *aureus* (MSSA) and 6 cases of methicillin-resistant *S*. *aureus* (MRSA). The second most common were *Klebsiella* species (n = 12, 28.6%) including 10 cases of *Klebsiella pneumonia* and 2 cases of *Klebsiella oxytoca*, followed by *Streptococcus* species (n = 5, 11.9%), *Enterobacter* species (n = 4, 9.5%), *Pseudomonas aeruginosa* (n = 3, 7.1%), and *Acinetobacter baumannii* (n = 2, 4.8%). Comparison of the clinical characteristics of EBTB patients with or without microorganisms isolated in bronchial washing is shown in [Table 4](#pone.0234558.t004){ref-type="table"}. Consolidation in chest CT findings tended to be more frequent in patients with microorganisms isolated (71.4%) than those without microorganisms isolated in bronchial washing (56.3%; *P* = 0.082). There were no differences in baseline characteristics, symptoms, or laboratory and bronchoscopic findings. Additionally, comparison of the clinical characteristics of EBTB patients with or without *S*. *aureus* isolated in bronchial washing is presented in S1 Table of the [S1 Appendix](#pone.0234558.s001){ref-type="supplementary-material"}. There were no differences in baseline characteristics, symptoms, or laboratory and CT or bronchoscopic findings either.

10.1371/journal.pone.0234558.t003

###### Microbiological characteristics of bronchial washing fluid.

![](pone.0234558.t003){#pone.0234558.t003g}

                                            Overall (*n* = 216)
  ----------------------------------------- ---------------------
  Patients with detected microorganisms     42 (19.4%)
   Single microorganisms                    36 (16.7%)
   Poly-microorganisms                      6 (2.8%)
  Total number of isolated microorganisms   19
  Identification of microorganisms          
   *Staphylococcus aureus*                  14 (33.3%)
    MSSA                                    8
    MRSA                                    6
   *Klebsiella* species                     12 (28.6%)
    *Klebsiella pneumoniae*                 10
    *Klebsiella oxytoca*                    2
   *Streptococcus* species                  5 (11.9%)
    *Streptococcus agalactiae*              1
    *Streptococcus anginosus*               1
    *Streptococcus constellatus*            1
    *Streptococcus haemolyticus*            1
    *Streptococcus pneumoniae*              1
   *Enterobacter* species                   4 (9.5%)
    *Enterobacter cloacea*                  3
    *Enterobacter aerogenes*                1
   *Pseudomonas aeruginosa*                 3 (7.1%)
   *Acinetobacter baumannii*                2 (4.8%)
   *Neisseria* species                      2 (4.8%)
   Miscellaneous                            6 (14.3%)
    *Aeromonas hydophilia*                  1
    *Citrobacter koseri*                    1
    *Enterococcus* species                  1
    *Escherichia coli*                      1
    *Proteus mirabilis*                     1
    *Stenotrophomonas maltophilia*          1

Values are presented as count (percentage).

MRSA, methicillin-resistant *Staphylococcus aureus*; MSSA, methicillin-sensitive *Staphylococcus aureus*

10.1371/journal.pone.0234558.t004

###### Comparison of clinical characteristics with or without microorganisms in bronchial washing fluid.

![](pone.0234558.t004){#pone.0234558.t004g}

                                                              Microorganisms         *p*-value              
  ----------------------------------------------------------- ---------------------- ---------------------- ----------
  Age, years                                                  74 (61--78)            72 (54--79)            0.362
  Gender, female                                              25 (59.5%)             117 (67.2%)            0.368
  Body mass index, kg/m^2^                                    21.2 (19.3--23.6)      21.4 (19.9--23.7)      0.716
  Ex or current smoker                                        14 (33.3%)             47 (27.0%)             0.447
  Comorbidities                                                                                             
   History of MTB treatment                                   9 (21.4%)              23 (13.2%)             0.224
   Diabetes                                                   8 (19.0%)              39 (22.4%)             0.835
   Chronic kidney disease                                     1 (2.4%)               8 (4.6%)               \> 0.999
  Respiratory symptoms[\*](#t004fn001){ref-type="table-fn"}                                                 
   Cough or sputum                                            22 (52.4%)             110 (63.2%)            0.219
   Hemoptysis                                                 2 (4.8%)               10 (5.7%)              \> 0.999
   Asymptomatic                                               12 (28.6%)             49 (28.2%)             \> 0.999
  Chest CT findings[\*](#t004fn001){ref-type="table-fn"}                                                    
   Consolidation                                              30 (71.4%)             98 (56.3%)             0.082
   Cavity                                                     8 (19.0%)              23 (13.2%)             0.333
  Laboratory findings                                                                                       
   White blood cell, /μL                                      6,680 (5,470--8,773)   6,860 (5,565--8,585)   0.804
   Erythrocyte sedimentation rate, mm/h                       47 (29--64)            51 (29--68)            0.416
   C-reactive protein, mg/dL                                  1.40 (0.45--3.58)      1.93 (0.50--5.56)      0.382
  Bronchoscopic finding                                                                                     
   Actively caseating                                         17 (40.5%)             97 (55.7%)             0.086
   Edematous-hyperemic                                        8 (19.0%)              24 (13.8%)             0.467
   Fibrostenotic                                              9 (21.4%)              24 (13.8%)             0.235
  Site involved[^‡^](#t004fn002){ref-type="table-fn"}                                                       
   Trachea                                                    2 (4.8%)               9 (5.2%)               \> 0.999
   Main bronchi or RBI                                        5 (11.9%)              37 (21.3%)             0.198
   Lobar bronchi                                              38 (90.5%)             156 (89.7%)            \> 0.999
  Multiple levels involved                                    3 (7.1%)               26 (14.9%)             0.217

\* Cases are duplicated.

^‡^ EBTB with multiple-level involvement was counted for each involvement.

Values are presented as median (interquartile range) or count (percentage).

MTB, *Mycobacterium tuberculosis*; CT, computed tomography; RBI, right bronchus intermedius

Discussion {#sec013}
==========

This study investigated the composition of bacteria in the lower respiratory tract at patients with EBTB. We demonstrated that 19.4% of EBTB patients had microorganisms in bronchial washing specimens. With the exception of MTB, the most common bacteria included *S*. *aureus* followed by *Klebsiella*, *Streptococcus*, and *Enterobacter* species.

The lungs have traditionally been considered sterile, but a growing number of studies have shown that the lung and the respiratory tract contain a diverse community of microorganisms \[[@pone.0234558.ref019]\]. The constitution of intrapulmonary microorganisms is affected by the dynamics of microorganisms immigration and elimination in the respiratory tract \[[@pone.0234558.ref020]\]. Furthermore, airway epithelial cells play a central role in the dynamics of microorganisms by various mechanisms, including structural barrier function, mucociliary clearance, and the production of antimicrobial peptides (AMPs), reactive oxygen (ROS), and a range of cytokines, chemokines and growth factors \[[@pone.0234558.ref021], [@pone.0234558.ref022]\].

Chronic lung disease induces persistent airway epithelial cell damage, which can affect regional growth conditions and the respiratory microbial community, and changes in lung microorganisms contribute to the progression of underlying lung diseases, establishing a vicious cycle of disease \[[@pone.0234558.ref023]\]. Previous studies have shown that some structural lung diseases have specific patterns of composition in the respiratory bacterial community that can be associated with the pathogenesis and prognosis of disease \[[@pone.0234558.ref008], [@pone.0234558.ref010], [@pone.0234558.ref024]\]. The most frequently isolated bacteria in COPD patients are *Haemophilus influenzae* and *Pseudomonas aeruginosa*, and *P*. *aeruginosa* colonization is also reported to be associated with exacerbations \[[@pone.0234558.ref025]\]. Recent studies have found a relative abundance of *Staphylococcus* and *Streptococcus* species in patients with idiopathic pulmonary fibrosis and have suggested its possible association with the pathogenesis of disease \[[@pone.0234558.ref012], [@pone.0234558.ref026]\]. In bronchiectasis, the role of respiratory microorganisms has been largely investigated in the same manner \[[@pone.0234558.ref027]\]. Frequently isolated and potentially pathogenic microorganisms include *H*. *influenza*, *P*. *aeruginosa*, and *Streptococcus pneumonia*. *P*. *aeruginosa* is associated with impaired lung function and increased mortality in bronchiectasis \[[@pone.0234558.ref010], [@pone.0234558.ref028]\].

In pulmonary tuberculosis, several studies have described the characteristics of the lung microorganisms as well \[[@pone.0234558.ref029], [@pone.0234558.ref030]\]. The respiratory bacterial composition in patients with pulmonary tuberculosis showed more diversity than those of healthy controls in its composition and many unique bacteria such as *Stenotrophomonas*, *Cupriavidus*, *Caulobacter*, *Pseudomonas*, *Thermus*, and *Sphingomonas* were found \[[@pone.0234558.ref030]\]. Additionally, respiratory bacterial pathogens were detected in sputum at 29% patients, and the common organisms were *H*. *influenzae* (21%) and *S*. *pneumonia* (8%) \[[@pone.0234558.ref029]\]. Some studies have reported a possible association between the presence of respiratory microorganisms and poorer prognosis in pulmonary tuberculosis \[[@pone.0234558.ref029], [@pone.0234558.ref031]\].

However, respiratory microorganisms in patients with EBTB have not been investigated in the literature. The reported prevalence of bacterial co-infection in patients with pulmonary tuberculosis varies greatly (from 17% to 44%) \[[@pone.0234558.ref029], [@pone.0234558.ref031], [@pone.0234558.ref032]\]. In this study, the prevalence of bacterial co-infection in patients with EBTB was 19%. In addition, the most common respiratory microorganism in EBTB was *S*. *aureus* isolated in 33.3% of the patients with detected microorganisms, followed by *Klebsiella* and *Streptococcus* species. These findings show that the microorganisms in EBTB are distinct from the other respiratory diseases discussed above. *H*. *influenza* and *P*. *aeruginosa*, which are the most common microorganisms in COPD and bronchiectasis, were isolated in 0 and 3 (7.1%) of patients in our study.

Interestingly, *S*. *aureus*, the most common bacterial isolate in this study, is a well-established predominant potential pathogen in patients with cystic fibrosis \[[@pone.0234558.ref033]\]. Further, this microorganism is frequently isolated in patients with MTB based on previous studies \[[@pone.0234558.ref031], [@pone.0234558.ref032]\]. *S*. *aureus* attaches primarily to the mucus component of the airway epithelium and can evade the host immune response and cause persistent colonization by biofilm formation \[[@pone.0234558.ref034]\]. Further studies are needed to establish the predominance of *S*. *aureus* in EBTB and its clinical significance.

This study has some limitations. First, this is a retrospective study so we could not investigate the causal relationship between microorganisms and EBTB. Second, there was no statistical significance for clinical differences between patients with or without bacteria isolated in the bronchial washing. Since many of the patients diagnosed with EBTB in this tertiary referral hospital had been later transferred to regional centers for follow-up care, there were some limitations on data collection for the treatment outcomes such as the presence of bronchial stenosis after treatment completed or changes in pulmonary functions of these patients. Further investigations are needed on the clinical significance of these organisms. Third, bacterial identification in bronchial washing was done according to conventional culture methods, so microorganisms information on non-culturable bacteria could not be determined. Finally, we did not exclude patients who received antibiotics prior to the study. However, most patients with EBTB are referred to a tertiary referral hospital without improvement during antibiotic treatment, which may reflect the real-world clinical setting.

Conclusions {#sec014}
===========

A variety of microorganisms were isolated in the lower respiratory tract at patients with EBTB and changes in the composition of microorganisms take place in the airways of those with EBTB. Further studies are needed to investigate the clinical significance of this finding.
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